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TIncreasing the intensity of radiation therapy and 
chemotherapy in the management of cancer has increased 
the incidence of adverse effects, especially oral mucositis. 
Aim and methods: a bibliographical review was conducted 
on the definition of oral mucositis, its clinical findings, 
the incidence, its etiology, the pathofisiology, associated 
morbidity, prevention and treatment. Results: current 
studies define oral mucositis as a very frequent and painful 
inflammation with ulcers on the oral mucosa that are covered 
by a pseudo membrane. The incidence and severity of lesions 
are influenced by patient and treatment variables. Oral 
mucositis is a result of two major mechanisms: direct toxicity 
on the mucosa and myelosuppression due to the treatment. 
Its pathofisiology is composed of four interdependent phases: 
an initial inflammatory/vascular phase&#894; an epithelial 
phase&#894; an ulcerative/bacteriological phase&#894; 
and a healing phase. It is considered a potential source 
of life-threatening infection and often is a dose-limiting 
factor in anticancer therapy. Some interventions have been 
shown to be potentially effective to prevent and treat oral 
mucositis. Further intensive research through well-structured 
clinical trials to obtain the best scientific evidence over the 
standard therapy of oral mucositis is necessary to attain ideal 
parameters for radiotherapy and chemotherapy.
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INTRODUCTION
Estimates show that there will be 472,050 new ca-
ses of cancer in Brazil in 2006.1 Added to the morbidity 
of cancer, its treatment causes significant side effects, 
many of which present in the mouth. In other words, 
mouth cancer causes alterations in the oral cavity, but 
the treatment used for neoplasms in general may also 
yield similar effects.2,3 
There are three commonly used approaches to 
treating malignant neoplasms: surgery, radiotherapy and 
chemotherapy. Surgical treatment of cancer has two 
main objectives: to resect the tumor and other tissues in-
volved, such as lymph nodes, and to remove endocrine 
organs that may alter and disseminate the disease. Diffe-
rent from surgery, radiotherapy and chemotherapy are 
not tissue-specific; they act by inhibiting rapidly-dividing 
cell growth, interfering with cell division mechanisms.4 
As chemotherapy and radiotherapy do not differentiate 
between rapidly dividing cancer cells and normal cells 
that divide at higher rates, such as those in the mouth 
or the bone marrow, they may result in side effects that 
present in the mouth.2-8 Furthermore, the mouth harbors 
many bacteria, which may facilitate access to infectious 
microorganisms into a myelosuppressed host. 3,4,9 
According to Sonis et al.4, the frequency of mouth 
problems in patients undergoing chemotherapy de-
pends on a number of variables. These variables may 
be related to the patient or to the treatment. Patient-
related factors are age, the diagnosis and the state of 
the patient’s mouth before and during treatment. Tre-
atment-related variables are the type of drug, the dose 
and frequency of therapy, and the use of concomitant 
treatment.
Commonly used medication in chemotherapy in-
cludes antimetabolic drugs, such as methotrexate, which 
inhibit DNA synthesis and tend to produce mucositis. 
Similar effects are seen with alkylating agents, such as 
5-fluorouracil, used frequently in the treatment of gas-
trointestinal tract malignant tumors. Antibiotics, such as 
adriamycin, may cause direct effects in the mouth, or 
side effects as a result of its action on accessory salivary 
glands. Plant alkaloids rarely cause direct derangement 
of the oral mucosa, but may affect the mouth as a result 
of their neurotoxic effects.4 
A common practice is to increase the intensity of 
therapy to raise primary cure rates.10 Unfortunately, the 
toxicity of chemotherapy tends to yield severe adverse 
effects, which limits medical treatment. In these cases, 
the most effective dose cannot be given, which reduces 
the response of tumors to therapy. 3,8,10-14 
The most common oral complications asso-
ciated with cancer therapy are as follows: stomatitis, 
infection, bleeding, mucositis, pain, loss of function 
and xerostomy.15 Sonis et al.4 divided oral complica-
tions of cancer chemotherapy into two main forms 
according to the origin, as follows: problems resulting 
from the direct action of the drug over mouth tissues 
- direct stomatotoxicity - and mouth problems caused 
by changes in other tissues - indirect stomatotoxicity 
- such as the bone marrow. The most common form of 
direct stomatotoxicity is mucositis, a diffuse ulcerative 
condition usually in the non-keratinized oral mucosa, 
involving mostly the soft palate, the jugal mucosa, 4,9,16,17 
the lateral border of the tongue, the wall of the pharynx, 
the tosillar pillars,4 the lips, the middle portion of the 
tongue and the floor of the mouth. 9,16,17 
This paper aims to present physicians and other 
professionals who support the treatment of cancer 
patients with information about chemotherapy and 
radiotherapy-induced oral mucositis. This review of 
the pertinent literature includes the definition, clinical 
findings, incidence, etiology, pathophysiology, associa-
ted morbidity, prevention and treatment of this form 
of oral mucositis.
 REVIEW OF THE LITERATURE
 
Definition and clinical features
Oral mucositis is defined as inflammation and 
ulceration of the mouth mucosa12,15 with pseudomem-
brane formation;11 it is a potential source of infection 
which may lead to death.12,15 This condition is a fre-
quent and painful debilitating effect of radiotherapy 
and chemotherapy for cancer, affecting over 40% of 
patients.12 
The initial presentation is erythema followed by 
white desquamating plaques, which are painful when 
touched. Epithelial crusting and a fibrin exsudate result 
in a pseudomembrane and ulceration, which is the 
more pronounced form of mucositis. Patients invariably 
complain of pain. Exposure of the richly innervated 
underlying stromal connective tissue due to loss of 
epithelial cells is found in the most severe form of 
mucositis;16 this condition is usually seen 5 to 7 days 
following medication.9  
Ulcers lead to severe pain that frequently requi-
res dietary changes and parenteral narcotics for relief. 
Ulcerated mucositis in myelosuppressed patients may 
become a portal for systemic invasion by bacteria or 
bacterial cell wall products.11 
According to Bensadoun et al.17 the pathology of 
mucositis shows a shallow ulcer, probably caused by 
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depletion of the basal epithelial layer, with subsequent 
denudation. The healing response to this injury compri-
ses an inflammatory cell infiltrate, an interstitial exsudate 
and the remains of cells and fibrin, which result in a 
pseudomembrane that is analogous to an eschar in a 
superficial skin lesion. This membrane appears white or 
opaque when hydrated by saliva. It may appear yello-
wish or greenish due to superficial infection, particularly 
if there are deep ulcers.18 Food, beverages or topical 
medication may also change the color. Careful inspec-
tion frequently reveals the slightly elevated membrane 
above the level of the underlying mucosa if the lesion 
is ulcerated. It may easily be mistaken for candidiasis. 
Secondary infection of the ulcer by Candida albicans 
may occur.11 Mild trauma may remove the membrane, 
causing bleeding and ulceration. Increased ulcer size 
results in a wider adjacent pseudomembrane that covers 
neighboring geographically connected ulcers. Insuffi-
cient cell regeneration results in epithelial atrophy and 
thinning of the mucosa.16 
The reaction is confined to the irradiated area in 
radiotherapy, frequently seen as a mucosal margin of 
intense erythema.16 The severity depends on a variety of 
factors, including the dose of medication, dose interval, 
the volume of treated tissue and the type of radiation.16,19 
Other factors are prior exposure to chemotherapy, 
concomitant chemotherapy, and systemic diseases such 
as diabetes mellitus or vascular conditions.19 In most 
patients healing occurs two or three weeks after the end 
of conventionally fractionated radiotherapy.16 
Various methods to assess the grade of mucositis 
in cancer patients have been described; these are based 
on the presence of signs such as erythema and lesions 
in isolation or associated with symptoms such as pain 
and swallowing difficulties.16,20 
Oral mucositis may be classified into five grades 
according to the World Health Organization grading 
system, as follows: grade 0 - indicated absence of mu-
cositis; grade 
I - presence of a painless ulcer, erythema or mild 
sensitivity; grade 
II - presence of painful erythema or ulcers that 
do not interfere with the patient’s ability to take food; 
grade 
III - confluent ulceration that interfere with the 
patient’s ability to take solid food; and grade IV - severe 
symptoms requiring enteral or parenteral support.17 
 
Incidence
Anticancer treatment-induced oral mucositis is a 
frequent complication;15 its incidence varies with pa-
tient-related and treatment-related variables (Table 1).
Generally, malignancies of the blood - such as 
leukemia and lymphoma - that suppress the bone mar-
row, tend to show a high rate of oral complications.4 
These patients develop problems in the mouth two or 
three times more frequently than patients that have 
solid tumors.21 This is probably associated with the 
disease, drug-induced immunosuppression and the 
frequent use of chemotherapy that specifically targets 
the cell cycle.22 
According to Childers et al.2 and Sonis et al.4, 
younger age increases the possibility of chemotherapy 
affecting the mouth. Around 40% of all chemotherapy 
patients present side effect in the mouth; this number 
reaches 90% in children under 12 years of age. It seems 
likely that the high mitotic rate of oral mucosa cells in 
this age group is an adjuvant factor.4 Notwithstanding 
its high prevalence, a few studies reporting a lower in-
cidence and severity of oral mucositis in children have 
been published.23 
As to the type of treatment, Adamietz et al.15 have 
reported that mucositis may be seen in nearly every 
patient when chemotherapy and radiotherapy are used 
simultaneously.
Parulekar et al.16 have estimated that chemothe-
rapy-induced mucositis varies from 40 to 76% in pa-
tients treated respectively with standard and high-dose 
chemotherapy.
Nearly all (90% to 97%9,24) patients receiving 
radiotherapy in the head and neck will develop some 
degree of mucositis.16 Of these patients treated with 
radiotherapy with or without chemotherapy, 34% to 
43% will present severe mucositis. As a result, the 
patient’s quality of life is affected, hospital admittance 
rates are higher, the use of total parenteral nutrition 
is increased and interruption of treatment is more fre-
quent, all of which compromise tumor control. Mucositis 
Table 1. Variables that affect the incidence of anticancer treatment-
induced oral mucositis.
Patient-related variables Treatment-related variables
Diagnosis4 Chemotherapy drug4 
Age4 Drug dosage and frequency4 
Level of oral health4,11 Irradiated region17,22 
Systemic conditions15 Irradiated tissue volume17,22 
 Type of ionizing radiation17,22 
 
Fractionated dose and cumula-
tive dose of radiotherapy17,19,22 
 
Concomitant chemo and 
radiotherapy23 
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Mucositis is a consequence of two major me-
chanisms: direct toxicity due to the treatment and 
myelosuppression that results from therapy. Its patho-
genesis is reduced cell renewal in the basal epithelial 
layers as a result of chemotherapy and radiotherapy; 
adequate replacement of desquamated cells becomes 
insufficient.4 
Cell kinetics initially defines the relative sensitivity 
of normal tissues to anticancer therapy. Oropharyngeal, 
intestinal and bone marrow cells divide rapidly and are 
more sensitive to radiation and chemotherapy compared 
to cells that divide slower and senescent cells in other 
parts of the body. Both radiation and chemotherapy 
cause cell death by interfering on their growth and 
differentiation mechanisms. Dividing cells are more 
sensitive to the effects of anticancer therapy.16 
Cells in the oral mucosa have high mitotic, cell 
renewal and epithelial maturation rates. This mucosa is, 
thus, vulnerable to the side effects of chemotherapy.5,20 
The non-specific effects of cytotoxic drugs used in the-
rapy reduces the rate of epithelial cell renewal, leading 
to muscle atrophy, localized or diffuse mucosal ulcers 
and inflammation.25 Chemotherapy not only alters 
mucosal integrity, but also changes the microbial flora 
in the mouth; it also alters the quantity and composi-
tion of saliva and epithelial maturation.20 The mucosal 
barrier is compromised, which is also a risk factor for 
morbidity and mortality in cancer and myelosuppressed 
patients.
According to Adamietz et al.15 the origin of cancer 
radiotherapy-induced mucosal lesions is radiobiological 
or toxic, although infection may further development. 
Damage to the oral mucosa may lead to infection, whi-
ch is maintained by immune unbalances, in particular 
leukopenia. Damage to salivary glands reduce the flow 
and composition of saliva and its pH, which is followed 
by changes in the oral microflora, again increasing 
the risk of infection. Chemotherapy-induced damage 
differs from that of radiation in that radiation damage 




In 1998 a new theoretical model was described 
for the pathophysiology of radiotherapy-induced mu-
cositis. This model included the knowledge at the time 
about cytokine activity and integrated local immunolo-
gical and microbacterial effects with the theory of direct 
and indirect toxicity. Thus, the pathophysiology of oral 
mucositis was described as having four interdependent 
phases, as follows:11 
1. a vascular/inflammatory phase,
2. an epithelial phase,
3. an ulcerative/bacteriological phase,
4. and a repair phase. 
Oral mucositis appears to be the consequence of 
a series of biological events that begin in the submuco-
sa and progress towards the epithelium.26 During such 
events, radiotherapy activates transcription factors.
During the first phase, pro-inflammatory cytoki-
nes, including interleukin 1 (IL-1) and the tumor ne-
crosis factor a (TNF-a), are produced and mediate a 
local response to therapy, followed by apoptosis and 
cell damage. The dynamic biological cascade results in 
injury to the mucosa, frequently presenting as ulcers. 
A fibrin exsudate containing bacteria - also called the 
pseudomembrane - covers the ulcer. Cell wall remains 
originating from colonizing bacteria penetrate the sub-
mucosa, where they activate macrophages in the infil-
trate; these macrophages produce additional cytokines. 
These and other related cytokines are responsible for 
causing direct tissue damage, dilation of blood vessels 
and other inflammatory effects, all of which increase 
the deposition of cytotoxic drugs on the mucosa. These 
effects mediate the transition to the next phase. Some 
authors have suggested that genetic differences in the 
inflammatory response may be responsible to varia-
tions in susceptibility to chemotherapy-induced oral 
mucositis.11 
The second phase (epithelial phase) is related to 
the previous model of direct stomatotoxicity in which 
cytotoxic agents inhibit the replication of epithelial 
basal cells, leading to a reduced capability for tissue 
renewal.
It is assumed that the third phase (ulcer with in-
fection) derives from trauma on the epithelium, which 
at this point is thinner and atrophic due to chemothe-
rapy. It is further postulated that bacterial colonization 
of ulcerated surfaces increases the quantity of pro-in-
flammatory cytokines in the mucosa, which facilitates 
systemic infection in a myelosuppressed host.
The repair phase takes place after 2 to 3 weeks 
in non-myelosuppressed patients that receive no fur-
ther therapy.22 Secondary infection may delay healing 
of mucosal lesions. Larger and deeper ulcers usually 
require more time to heal. The profound depletion 
of mesenchymal cells may result in second intention 
healing. Depending on the extent of injury, the re-
sulting mucosa may appear pallid, atrophic and less 
complacent. A few deep ulcers may never heal and 
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may progress to soft tissue or bone necrosis. Although 
systematic clinical trials of these pathological changes 
have not been conducted in human beings, deep ulcers 
that require prolonged healing times probably produce 
what is clinically noted as late effects on the mucosa. 
The peak of severity of lesions only indicates partially 
the degree of mesenchymal cell depletion. The duration 
of injury also reflects the degree of cell depletion and 
the recovery rate.17 
Although there have been recent conceptual 
developments, certain pathophysiological processes 
that favor anticancer therapy-induced mucositis have 
not been fully clarified.6,24,27-30 According to Barasch 
and Peterson27 clinical controversy persist. Cell and 
molecular studies are difficult to undertake in cancer 
patients. Furthermore, animal models are inherently 
limited. Thus, additional evidence from epidemiology 
and risk factors are needed to further understand the 
pathophysiology of mucositis.
 
Morbidity associated with mucositis
Mouth lesions may become the entry point 
for the dissemination of bacterial, fungal and virotic 
infection,2,8,30,31 particularly in patients undergoing 
myelosuppressive or immunosuppressive chemothe-
rapy regimens for the treatment of cancer. In many 
medical centers, cancer patients undergoing high-dose 
chemotherapy usually receive antibiotics and antifungal 
medication preventively or during the periods of drug-
induced leukopenia.21 A study by Nicolatou-Galitis30 re-
vealed that 29.1% of patients presented herpes simplex 
virus infection, which worsens radiotherapy-induced 
ulcerative oral mucositis.
This significant acute clinical side effect of anti-
cancer therapy leads to discomfort and pain and hinders 
adequate nutrition; it may even cause an interruption 
of mediation or changes in the drug regimen. These 
effects may increase hospital stay and increase conside-
rably the risk of infection and death in some patients.4 
Furthermore, secondary infection may result in severe 
systemic infection.2,3,7,8,10,14,16,17,19,30-34 Mucositis may lead 
to potentially fatal bacteremia in myelosuppressed 
patients. All of these conditions may obstruct further 
treatment or increase its cost, threatening the survival 
of patients or permanently changing their quality of life 
and that of their families.
It is clinically difficult, if not impossible, to dis-
criminate between infected and non-infected mucositis. 
An association between these two types occurs almost 
always, resulting in a thinned mucosa, pseudomembra-
nes, erythema and ulcers.
 
Prevention and Treatment
Although this condition has been studied in 
detail, no approach has been demonstrated to be 
effective in the prevention and/or treatment of oral 
mucositis. Recent systematic reviews and clinical trials 
have identified potentially effective approaches for the 
prevention of mucositis, namely: the use of allopuri-
nol, growth factors and povidine-based mouthwashes, 
hydrolytic enzymes, amiphostine,15,29,36 sucralfate13,37 
and antibiotics,29,36,38,39 honey,19 low-intensity laser,17,2
2,29,35,36,38,40,41 oral hygiene,25,42 analgesics10 and anti-in-
flammatory drugs, and other options.5,8,11,15,20,28,29 The 
evidence for these measures, however, is variable 
and the benefits for patients with different cancers is 
unknown.13,14,27,36,40,43,44 The prevention and treatment of 
mucositis remains an unsolved problem that limits the 
efficacy of anticancer therapy and reduces the quality 
of life of these patients.12 
One of the major concerns during the Mucositis 
Committee meetings in 200045 was the lack of trials 
and the empiricism of the methods used at the time 
for the prevention and treatment of mucositis; many of 
the strategies were considered as reasonable (such as 
mouthwashes with saline). It was underlined, however, 
that a strict review would probably reject those measu-
res. The authors underlined the challenge to reach an 
adequate protocol that researchers would accept and 
put in practice.
FINAL COMMENTS
Oral mucositis is a frequent and debilitating 
intercurrence in patients undergoing chemotherapy 
and radiotherapy for the treatment of various forms of 
cancer. With the use of more aggressive approaches, 
mucositis as a limiting factor is becoming more evident; 
its control is one of the priorities in clinical oncology. 
The past decades have seen advances in the knowled-
ge of the pathophysiology of this condition. There is, 
however, no consensus on the effectiveness of a variety 
of measures used in the prevention and treatment of 
oral mucositis. New well-structured trials are needed to 
define the standard treatment for managing mucositis. 
This will alleviate pain, favor nutrition and increase the 
quality of life of these patients.
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